Moleculin Biotech, Inc.
(NASDAQ : MBRX)

( )
MBRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
LLYEli Lilly & Co. 1.08%365.631.1%$1192.52m
JNJJohnson & Johnson 0.12%177.220.7%$1097.25m
MRKMerck & Co., Inc. 0.60%107.460.7%$994.87m
PFEPfizer Inc. 0.72%49.200.9%$981.12m
ABBVAbbVie, Inc. 0.14%159.611.9%$906.78m
BMYBristol-Myers Squibb Co. 0.16%79.271.1%$751.13m
AZNAstraZeneca Plc 0.08%66.171.0%$360.17m
IDXXIDEXX Laboratories, Inc. -1.24%411.363.9%$222.64m
GSKGSK Plc 0.89%33.990.3%$202.02m
HZNPHorizon Therapeutics Plc 0.97%78.285.4%$201.37m
NVSNovartis AG 0.57%87.790.2%$190.04m
CTLTCatalent, Inc. -1.83%41.411.9%$163.88m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%212.728.0%$159.13m
NVONovo Nordisk A/S 0.86%118.840.1%$155.62m
SGENSeagen Inc. -0.42%123.445.7%$122.67m

Company Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.